import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-immunology-biologics-market-report';

/**
 * Curated copy for the UAE immunology & biologics programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 320–380M 2026 → ~USD 571M 2030, ~12–13% CAGR).
 * Detail: MOHAP/DHA/DOH, mandatory insurance step therapy, private-payer biologics coverage; epidemiology cited as published ranges.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_IMMUNOLOGY_BIOLOGICS_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Immunology & Biologics Market Report 2026',
  metaTitle: 'UAE Immunology & Biologics Market Report 2026 | BioNixus',
  metaDescription:
    'UAE immunology & biologics market ~USD 320–380M in 2026 (BioNixus analysis): MOHAP/DHA/DOH access, mandatory-insurance step therapy for IL-17/IL-23 & JAK, private-payer biologics coverage, biosimilars—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing reads UAE immunology and biologics through its payer logic: an affluent, heavily insured, expatriate-rich population, three regulators, and mandatory-insurance step-therapy ladders that differ by emirate—mapping where prior authorization, not MOHAP registration, gates IL-17, IL-23, and oral JAK therapy across rheumatology, dermatology, and gastroenterology.',
  summaryPara1:
    'The UAE is a premium immunology and biologics market where access is shaped less by registration than by mandatory-insurance medical policy. BioNixus sizes the market at roughly USD 320–380 million in 2026, advancing toward about USD 571 million by 2030 at low-double-digit CAGR—driven by a high-income, insured, and largely expatriate population, strong private-payer biologics coverage, and rising biosimilar use for cost control. Anti-TNF agents and their biosimilars anchor volume; IL-17 and IL-23 inhibitors compete in psoriasis and psoriatic arthritis under step-therapy ladders that vary by emirate and insurer; IL-4Rα blockade (dupilumab) grows in atopic dermatitis and asthma; and oral JAK inhibitors expand on convenience while drawing safety-monitoring scrutiny aligned to FDA and EMA label warnings. Access turns on the three-authority landscape (MOHAP, DHA, DOH) and on insurer prior authorization. Sizing reflects BioNixus market analysis, 2026, applied alongside published prevalence ranges rather than unaudited panel extrapolation.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [GCC immunology & biologics market report](/market-reports/gcc-immunology-biologics-market-report) for Gulf-wide benchmarking, the [Saudi Arabia immunology & biologics market report](/market-reports/saudi-arabia-immunology-biologics-market-report) for the larger neighbouring market and its biosimilar tender dynamics, the [UAE biosimilars market report](/market-reports/uae-biosimilars-market-report) for substitution context, [immunology therapy research](/healthcare-market-research/therapy/immunology) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'MOHAP federal registration plus DHA and DOH facility requirements; mandatory-insurance step therapy and prior authorization for IL-17, IL-23, and JAK agents differing by emirate and payer (Thiqa, Daman, Dubai plans); premium private ward and clinic biologic carve-outs versus stricter step ladders on standard plans; biosimilar adoption used for private-payer cost control rather than centralized tendering; IL-4Rα (dupilumab) growth in atopic dermatitis and asthma where MOHAP labels are active; expatriate continuity-of-care and prior-treatment documentation gaps complicating step-therapy proof',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE immunology as a payer-segmented, emirate-specific market rather than a national one. Coverage for the same IL-17 or JAK agent can differ between an Abu Dhabi insurer and a Dubai plan, and between premium and standard products, so prior-authorization design and step-therapy documentation drive real uptake more than registration. We pair bilingual rheumatology, dermatology, and gastroenterology quantitative work with insurer and payer-medical-director depth, and we capture the expatriate dynamic—prior-treatment history from another country that step-therapy rules may not recognise, and continuity-of-care gaps when patients change insurers or employers. Operational gates still matter: TB screening before anti-TNF or IL-17 initiation, infusion capacity at private centres, and treat-to-target documentation insurers expect. Biosimilar use is shaped by private-payer cost control rather than the centralized tenders that dominate Saudi Arabia. KOL maps follow real referral and biologic-initiation influence.',
  commercialOutlookParagraph:
    'The outlook to 2030 favours teams that win insurer medical policy emirate by emirate. Biosimilars exert cost-control pressure through private payers rather than national tenders, so anti-TNF originators defend on device, indication breadth, and patient support, while IL-17, IL-23, IL-4Rα, and JAK classes compete on step-therapy positioning and safety narratives. The expatriate, insured population adopts new therapy quickly where coverage allows. Manufacturers should plan emirate-specific access dossiers, insurer engagement, and documentation that handles prior-treatment history for a mobile population. Because a relatively small set of insurers and premium centres shapes most volume, share assumptions should be stress-tested by emirate and payer archetype before regional revenue targets are locked.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—rheumatology, dermatology, and gastroenterology adoption surveys, insurer and payer medical-policy interviews, biosimilar confidence work, and access mapping where data is available. Epidemiology references use published UAE and regional prevalence ranges (including a high reported atopic-dermatitis burden in EAACI-aligned literature) as planning inputs, not patient-level forecasts. Because insurer medical policies and step rules update on short cycles, access statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the UAE immunology and biologics market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE immunology and biologics market at roughly USD 320–380 million in 2026, advancing toward about USD 571 million by 2030 at low-double-digit CAGR. Growth is driven by an affluent, insured, and largely expatriate population, strong private-payer biologics coverage, and rising biosimilar use for cost control. Use the GCC immunology & biologics market report for Gulf-wide context and the UAE healthcare market report for macro sizing.',
    },
    {
      question: 'How does insurance step therapy shape biologic access in the UAE?',
      answer:
        'Most biologic prescribing is insurance-funded, and step-therapy ladders and prior-authorization criteria for IL-17, IL-23, and JAK agents differ by emirate and payer. Abu Dhabi (including Thiqa and Daman-administered benefits) and Dubai plans apply different rules, and premium products often carry more generous biologic carve-outs than standard plans. The binding constraint is usually insurer medical policy rather than MOHAP registration. BioNixus tracks these payer rules directly so commercial teams can build emirate-specific access dossiers rather than a single national submission.',
    },
    {
      question: 'How are biologics and biosimilars regulated and reimbursed in the UAE?',
      answer:
        'MOHAP provides federal marketing authorisation, with DHA and DOH adding facility requirements for products used in their licensed hospitals. Biologics follow ICH-aligned dossier expectations with UAE-specific labelling and pharmacovigilance. Unlike Saudi Arabia’s national hospital procurement model, UAE biosimilar adoption is driven mainly by private-payer cost control and insurer formularies rather than centralized tendering. Teams should map MOHAP approval, DHA or DOH facility access, and then insurer prior-authorization and step rules for each target emirate and payer.',
    },
    {
      question: 'Which immunology classes are growing fastest in the UAE?',
      answer:
        'Anti-TNF agents and biosimilars anchor volume. IL-17 and IL-23 inhibitors grow in psoriasis and psoriatic arthritis under step-therapy positioning. IL-4Rα blockade (dupilumab) is a major growth driver in atopic dermatitis and asthma. Oral JAK inhibitors expand on convenience but face insurer scrutiny aligned to FDA and EMA safety warnings. Gastroenterology biologics tie adoption to infusion capacity and IBD referral depth. The affluent, insured population supports relatively fast uptake where coverage allows.',
    },
    {
      question: 'How does the expatriate population affect immunology access in the UAE?',
      answer:
        'A large share of UAE patients are expatriates who may have started biologic therapy in another country. Step-therapy rules that require documented prior conventional therapy can be hard to satisfy when records are incomplete or from abroad, and continuity of care can break when patients change employers or insurers. This complicates both initiation and switching. BioNixus captures these continuity-of-care and documentation realities in qualitative work so access and patient-support strategies reflect how a mobile, insured population actually moves through the system.',
    },
    {
      question: 'How does BioNixus help immunology and biologics teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE immunology programmes across rheumatology, dermatology, and gastroenterology: physician adoption studies, insurer and payer medical-policy interviews, emirate-level step-therapy and prior-authorization analysis, biosimilar confidence work, and KOL mapping tied to real referral and initiation pathways. Deliverables align to launch, access, or indication-expansion milestones and connect UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, step-therapy and access-risk maps, objection libraries, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
